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Abstract 
Introduction 
Vaccines incorporated into microneedle-based patch platforms offer advantages over conventional 
hypodermic injections. However, the success and clinical utility of these platforms will depend on its 
acceptance among stakeholders. Minimal focus has been placed on detpermining parents’ 
acceptability of microneedle-patch vaccines intended for paediatric use. This qualitative study probes 
the perceived acceptability of microneedle technology for paediatric vaccination in a parent 
population. 
Research Design and Methodology 
Focus groups (n = 6) were convened through purposive sampling of Cork city primary schools. 
Discussions were audio-recorded, transcribed verbatim, anonymised, independently verified and 
analysed by thematic analysis, with constant comparison method applied throughout. 
Results 
The opinions of 32 parents were included. All participants declared that their children were fully 
vaccinated. Five core themes were identified and defined as: (i) concern, (ii) suitability for paediatric 
use, (iii) potential for parental administration, (iv) the role of the healthcare professional and (v) 
special populations. Drivers for acceptance include; concerns with current vaccines and vaccination 
programmes; attributes of microneedle-patch (reduced pain, bleeding, fear and increased 
convenience) and endorsement by a healthcare professional. Barriers to acceptance include;  lack of 
familiarity, concerns regarding feasibility and suitability  in paediatrics, allergic potential, inability to 
confirm delivery and potential reduction in vaccine coverage. 
Conclusion 
This is the first study to explore parental acceptance of microneedle-patch vaccines. Capturing the 
opinions of parents, the ultimate decision makers in paediatric vaccination, is crucial in the 
understanding of the eventual uptake of microneedle technology and therefore adds to literature 
currently available. This study has revealed that even “vaccine-acceptors”; parents who agree with, or 
do not question vaccination, will question the safety and efficacy of this novel  method. Participants in 
this study remained tentative. However, the study has also revealed that healthcare professional 
endorsement could reduce this tentativeness, thereby identifying the role of healthcare professionals in 
disseminating information and providing support to parents. An increased awareness of developments 
in microneedle technology is needed to permit informed decision-making by parents.  
 
Introduction 
Microneedles are micron-sized needles, designed to achieve the efficacy of the conventional 
hypodermic injection with the simplicity of a skin patch (1, 2). Incorporating vaccines into 
microneedle-based patch platforms offer the possibility of reducing costs associated with current 
vaccination programmes: (i) their thermostability eliminates cold-chain transportation requirements, 
thereby reducing distribution costs (3-5); (ii) their potential for self-administration would reduce 
reliance on trained personnel, reducing administration costs (1, 6-8) and (iii)  their potential dose-
sparing characteristics would permit a reduction in vaccine antigen per dose, reducing production 
costs (9-11). In addition, microneedles may be fabricated using dissolving polymers, eliminating the 
biohazardous sharps waste associated with conventional vaccination methods (7, 12).  These 
dissolving microneedle-patches have been developed to successfully incorporate vaccines in vivo for 
multiple disease indications (13). The ability to penetrate the skin with minimal trauma, in the absence 
of pain and bleeding (1) has been identified by healthcare users as an important factor in their 
eventual clinical use (14, 15). 
Despite these desirable characteristics for healthcare professionals and vaccinees, the success and 
commercial viability of this technology will depend on its acceptance among these stakeholders. It is 
widely accepted that obtaining and evaluating public opinion on developing scientific, technological 
and medical innovation and policy is important (16, 17). The European Medicines Agency (EMA) 
recommends that evaluation of patient acceptability should be an integral component of 
pharmaceutical and clinical development (18). In their exploratory research study, Birchall et al., 
captured the perceived advantages of, and concerns with, microneedles, through the convening of 
focus groups comprising public participants and healthcare professionals (19). A high percentage of 
participants suggested that microneedles would be ‘ideal’ for the administration of medicines to 
children (19). In another study, children expressed a favourable viewpoint, suggesting that 
microneedle-based blood monitoring could offer an attractive alternative to conventional methods 
(20). This research was expanded to include parental perception of microneedle-mediated blood 
monitoring of their infants and, once again, support for the microneedle was evident (21). Research 
thus far has focussed on demonstrating safety and efficacy of microneedle-mediated delivery and 
assessing the acceptability of microneedle technology in general, with minimal focus on determining 
the acceptability of microneedle-patch vaccine delivery, in particular those intended for paediatric 
use. Therefore, to address this knowledge gap, this qualitative study probes the perceived 




The acceptability  of microneedle-patch vaccines was explored through a series of focus groups. 
Focus groups were chosen as they can provide insights into attitudes and beliefs that underlie 
behaviour and give context and perspective that enable experiences to be understood more holistically 
(22). These attitudes, feelings and beliefs may be partially independent of a group or its social setting 
but are more likely to be revealed via the social gathering and the interactions entailed within a focus 
group.  
A list of primary schools in Cork city, Ireland (n=50), detailing address, Principal name and contact 
details was compiled using information freely available from the Irish Department of Education and 
Skills (23). A recruitment poster, a copy of the informed consent form and a cover letter detailing 
study overview, addressed to each Principal, were sent via post. A follow-up email detailing the same 
information was sent one week later. With the permission of the Principal, contact was made with the 
Parent Association of those schools that expressed willingness to participate and focus group 
participants were recruited, using purposive sampling. Inclusion criteria included self-declared 
satisfactory English language and parent or guardian of a child or children less than 12 years of age, 
with no limitation placed on age or gender of participant. Focus groups took place within the grounds 
of the school, often coinciding with pre-arranged Parent Association meetings, to enhance 
convenience for participants. Written informed consent to take part in the study and to be audio-
recorded was obtained from participants prior to each focus group. Information detailing gender, age, 
highest level of education achieved (according to International Standard Classification of Education 
(ISCED) (24)), number of children less than 12 years of age in their care and the vaccination status of 
their children was obtained for each participant. 
A brief description of microneedle-patch vaccines, explaining their ability to disrupt the outer skin 
barrier layer and deliver a vaccine, without impinging on the underlying pain receptors and blood 
vessels, was provided by the moderator. This was considered necessary given the likely unfamiliarity 
of participants with microneedle technology. However, to mitigate against risk of introduction of bias, 
information relayed was of a factual nature only. A research prototype, placebo microneedle-patch 
was passed around the groups and a magnifying glass was provided, to permit visualisation of the 
individual microneedles, to act as a focussing exercise to stimulate discussion and to reduce bias by 
enabling the independent formation of opinions (Figure 1). A topic guide with a semi-structured 
design was used during each focus group, constructed based on a comprehensive literature search 
(25), providing general probes in an open-questioning style (Table 1). Ethical approval was obtained 
from the Social Research Ethics Committee, University College Cork. The authors declare that they 
have no competing interests. 

















Table 1 Focus group topic guide 
Opinions of vaccines  
What are your opinions on current paediatric vaccination programmes? 
Do you agree with current paediatric vaccination programmes? 
What are the benefits of vaccination programmes? 
What are your concerns about vaccination programmes? 
What are the problems with current vaccination programmes? 
Are you happy for your children to be vaccinated? 
Do you have any issues with current vaccination methods? 
Do you think cost is a major consideration with vaccination programmes? 
Opinions of microneedle-patch vaccines 
Before today, had you ever heard of a microneedle-patch vaccine? 
What is your initial opinion of the microneedle-patch vaccine? 
Do you believe that the microneedle-patch vaccine is as effective as other vaccination methods? 
Would you trust this vaccination method? 
Do you think there are any advantages of the microneedle-patch vaccine? 
What do you like about the microneedle-patch vaccine? 
Do you think there are any disadvantages of the microneedle-patch vaccine? 
What do you dislike about the microneedle-patch vaccine? 
Would you have any concerns in relation to the use of a microneedle-patch vaccine? 
Would you allow your child or a child in your care to be vaccinated using a microneedle-patch vaccine? 
Do you think the microneedle-patch vaccine could change opinions of vaccination? 
What would children think of the microneedle-patch vaccine? 
Do you think people would be nervous of the microneedle-patch vaccine? 
If given a choice, which method of vaccination would you prefer? 
Who do you think should administer the microneedle-patch vaccine? 
Do you think you would be able to self-administer the microneedle-patch vaccine? 
Would you be willing to administer the microneedle-patch vaccine to your child or a child in your care? 
Would you be comfortable with administering the microneedle-patch vaccine to your child or a child in your care? 
Is there any way you think the microneedle-patch vaccine could be improved? 
What do you think of the design of the microneedle-patch vaccine? 
Is there any way you think the design of the microneedle-patch vaccine could be improved? 
Do you think the Health Service Executive (HSE) should endorse and invest in the microneedle-patch vaccine? 
Focus group analysis 
Audio-recorded sessions, using a Dictaphone (OLYMPUS Digital Voice Recorder VN-731PC), were 
fully transcribed verbatim within one week of each focus group. Data were entered into QSR 
International’s NVivo V.11 software to assist analysis. Each participant was assigned an anonymised 
identifier; for example, the first participant of the first focus group was assigned FG1P1. Transcripts 
were verified against audio-recordings with a random sample verified by an independent researcher. 
Focus groups transcripts were independently coded by co-investigators. Disparities were identified 
and resolved through discussion. Data were analysed by thematic analysis, with constant comparison 
method applied throughout.  
Results 
Focus Group Participants 
Six focus groups were completed from 3
rd
 November 2015 to 12
th
 January 2016, representing an 
uptake rate of 12%. The opinions of 32 participants (29 female) were compiled. The most commonly 
reported age range was 30-39 years (46.88%), highest education level was Higher Education (ISCED 
level ≥ 4) (68.75%) and the number of child(ren) under 12 years in their care was two (46.88%). All 
participants declared that their children were fully vaccinated, to the best of their knowledge. A 
















Table 2 Participant demographics 
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ISCED level 3 
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*Highest education level 
 ISCED level 1: Primary education, equivalent to 8 years official State education 
 ISCED level 2: Lower secondary education: Irish Junior/Inter Certificate, equivalent to 11 years official State education   
 ISCED level 3: Upper secondary education: Irish Leaving Certificate, equivalent to 14 years official State education 
ISCED level ≥4:  Higher Education including post-secondary non-tertiary education, short-cycle tertiary education, Bachelor 
(or equivalent), Master (or equivalent) and Doctoral (or equivalent) 
  
 
Two of the six participating schools were included in the Delivering Equality of Opportunity in 
Schools (DEIS) programme, that is part of the Department of Education and Skills action plan which 
focusses on addressing and prioritising the educational needs of children from disadvantaged 
communities. Focus group duration ranged from 27 to 42 minutes (Table 3).  
Table 3 Focus groups:  DEIS status, gender breakdown and duration 
 DEIS*  Male (n) Female (n) Duration (mins) 
FG1 No 0 4 33 
FG2 Yes 0 5 42 
FG3 Yes 1 5 37 
FG4 No 0 5 27 
FG5 No 0 5 29 
FG6 No 2 5 33 
*DEIS: Delivering Equality of Opportunity in Schools 
 
 
Focus group analysis 
Focus groups transcripts were analysed by thematic analysis, with constant comparison method 
applied throughout. Five core themes were identified and defined as: (i) concern, (ii) suitability for 
paediatric use, (iii) potential for parental administration, (iv) the role of the healthcare professional 
and (v) special populations (Table 4). A pictorial representation of these themes, sub-themes and 
associated exemplar quotes is seen in Figure 2. 
Table 4 Themes and sub-themes and their occurrence in each focus group 
 Focus group 





























ii. Suitability for paediatric use 
Practicality 
Child-friendly design 

























iii. Potential for parental administration 
Benefits of parental administration 


























iv. The role of the healthcare professional 


















































• Current vaccines 
• Vaccine hesitancy 
• Safety and efficacy 
Concern 
• Practicality 
• Child-friendly design 
• Transfer of acceptability 
Suitability for 
paediatric use 
• Benefits of parental administration 
• Disadvantages of parental administration 




• Source of healthcare information 
The role of the 
healthcare 
professional 
• Allergic potential 
• Alternative uses 
Special 
populations 
“No one likes looking at a needle, no matter how brave you are” 
“I don’t think it’s the patch at all or the needles, I just think some 
people are just against vaccines no matter what” 




“You would have to monitor a child a lot more to make sure they 
keep it on and everything” 
“What about making them more child-friendly, like with Disney 
princesses or superheroes?” 
“But if it becomes an accepted norm for adults, then they’ll more 
easily put it on their kids 
 
“This is more casual and relaxed. Just like putting on a band aid” 
 
“You’d need to be told of shown first…before you did it yourself” 
 
“But even something that when you put it on and then when it 
changed colour or did something, 100%, you know it’s done” 
 
“I think if my doctor recommended this patch and trusted it, I would 
be happy with it” 
 
“Could kids be allergic to it? To the plaster part. People are allergic to 
plasters aren’t they?” 
 
“Like insulin for diabetics. I think a patch like this would be great…” 
 
i. Concern 
Concern emerged as a theme in all focus groups. Participants expressed concerns regarding current 
vaccination methods and programmes, such as unattractive visual appearance and hysteria associated 
with in-school programmes. In addition, participants discussed personal negative experiences with 
vaccines such as fear, parental and paediatric trauma, pain and side effects:  
FG6P6 “No one likes looking at a needle, no matter how brave you are” 
FG6P4 “Mass fainting, hysterical crying, nightmare to deal with. This is why I’m not sure these in-
school vaccine sessions are a good idea. I think it creates chaos” 
Some participants alluded to the behavioural phenomenon of vaccine hesitancy, despite declaring that 
all children in their care were fully vaccinated. 
 FG3P2 “Is it still as important today as it was 10 years ago to get these vaccinations?...if you listen to 
some media, people have gotten sicker because of these vaccinations and some people blame 
these vaccinations…my small one is after having the mumps even after getting the vaccine…is 
it really important to get them when you say it prevents these things but it’s still not 
preventing them”  
 FG3P2 “I don’t think it’s the patch at all or the needles, I just think some people are just against 
vaccines no matter what” 
Evidence of safety and efficacy was of paramount importance to parents, with all focus groups 
requiring reassurance that microneedle-patch vaccines would be as safe and efficacious as 
conventional vaccines.  
 FG1P3 “So they have done controls comparing with injection with needle and syringe to the patch?” 
FG2P3 “I actually, I love the idea of it in theory being able to give it but at the same time, before I’d 
give it to my child I’d want it to be tested in hundreds of thousands of people across the world 
for ideally at least 10 years”  
 FG6P7 “Well I think it sounds great, if it’s as good as the normal vaccine” 
 FG6P5 “It’s hard to believe the needles are big enough to give the vaccine, I mean, they’re tiny” 
 FG6P6 “By creating loads of holes in your skin are you not increasing the risk of picking up an 
infection?” 
ii. Suitability for paediatric use 
Focus groups participants acknowledged the advantages of microneedle-patch vaccines for paediatric 
use. These included a reduction in pain and bleeding and an attractive visual appearance. However, 
the practicality and feasibility of using a patch delivery system in a paediatric population was 
explored: 
 FG1P4 “If the child finds something on their arm, they will take it off” 
 FG2P5 “You would have to monitor a child a lot more to make sure they keep it on and everything” 
FG2P3 “I’m just thinking of the practicality though you know…if you’re using the thigh and what if 
they have an explosive nappy?”  
In addition, the current design of the patch was challenged and suggestions were offered to make the 
delivery system more ‘child-friendly’: 
 FG1P4 “If they are designing those and especially for children, they would want to make them child 
friendly, in other words put some type of funny face or something on the patch so that the 
child would keep them on”  
 FG1P4 “Make it completely invisible so the child doesn’t notice it” 
 FG3P4 “What about making them more child-friendly, like with Disney princesses or superheroes or 
something?” 
Focus groups discussed that acceptability for use in a paediatric population would be increased by an 
initial period of use in an adult population, permitting familiarisation with the microneedle 
technology: 
FG1P1 “But if it becomes an accepted norm for adults, then they’ll more easily put it on their kids” 
FG2P3 “If it was in widespread use as a technology for adults that we were more comfortable with it, 
familiar with it, you know that you’d be a bit more open to extending what’s normal for an 
adult to a child” 
iii. Potential for parental administration 
Participants acknowledged the potential benefits of parental administration, including convenience 
and a reduction in fear for the child: 
 FG1P1 “Avoids the hassle of having to go” 
FG3P2 “It would be a lot easier, as parents to put them on ourselves because bringing any child to a 
doctor is going to put fear in them anyway so doing it ourselves, it takes the fear factor 
completely out of it” 
FG6P4 “This is more casual and relaxed. Just like putting on a band aid” 
However, a large number of parents indicated a level of discomfort with administration to their own 
children. Many participants believed that healthcare professionals ought to administer the vaccine, 
regardless of the delivery system, while others recognised the benefits of parental administration but 
would prefer medical supervision and reassurance should they be administering the vaccine to their 
own child. Participants discussed the need for reassurance that the patches would be easy to use, with 
minimal guidance or training.  
FG1P2 “You’d need to be told or shown first…before you did it yourself” 
FG2P3 “How hard would you need to push, would you be literally ramming it against the skin?...my 
child I guarantee would end up with a bruised arm I’d be pushing so hard” 
FG3P2 “Like I presume there’s no danger with us putting them on ourselves, you know, there’s no 
special way to put them on or anything like that” 
In addition, participants raised concerns regarding the potential elimination of current vaccine 
surveillance and monitoring systems and reduced traceability that may be associated with wide-spread 
parental administration, suggesting that convenience may result in a level of complacency and /or 
non-compliance: 
FG1P4 “The HSE will send you out a letter to tell you your vaccination is due. If you don’t go, they 
will keep contacting you with letters…I know I would be quite lackadaisical, knowing it’s 
there and I can do it any time, I won’t do it” 
FG3P5 “People could genuinely forget, leave it in the cupboard and say I’ll do it later” 
FG1P1 “We’d have to put something in place or else we would have no idea who was vaccinated” 
Many groups discussed how the inclusion of a delivery indicator would be necessary to provide 
reassurance that the appropriate dose had been administered, with participants offering suggested 
alterations to the current patch system.  
FG2P1 “But even something that when you put it on and then when it changed colour or did 
something, 100%, you know it’s done” 
FG4P1 “Is there any way you could tell they got the full amount? Like if it just fell off or something 
when it was done dissolving” 
FG6P2 “It would be great if it changed colour or something, like change to green when it’s time to 
take it off and stay red when it’s dissolving or whatever. That could almost turn into a game 
and encourage the child to leave it on” 
iv. The role of the healthcare professional 
The pivotal role played by healthcare professionals, such as doctors, nurses and pharmacists, in 
guiding healthcare decisions and supervising and providing medical care was revealed.  
 FG4P5 “When the doctor told me to come in for the jabs, I just did” 
FG6P1 “I think if my doctor recommended this patch and trusted it, I would be happy with it. I have 
to rely on them for information because if you gave me all the clinical study information or 
whatever in the world, I would not understand it” 
FG1P3 “Even if the pharmacist would administer it. At least there’s some kind of monitoring then” 
v. Special populations 
Participants identified the potential for allergy associated with microneedle-patch vaccines, suggesting 
that this technology may be unsuitable for hypersensitive individuals. 
FG2P4 “Would you not expect reactions to occur, if dissolving in the skin, like allergy?” 
FG4P3 “Could kids be allergic to it? To the plaster part. People are allergic to plasters aren’t they?” 
FG5P3 “Or what if a child has very sensitive skin, would the patch irritate it?” 
Focus group participants discussed alternative uses for the microneedle-patch, without prompt. It was 
highlighted that because a microneedle-patch would cause less pain on administration, the technology 
could provide an attractive alternative in the treatment of a variety of conditions, where a needle and 
syringe are conventionally required. This was deemed particularly useful in situations where multiple, 
repeated injections are required.  
FG3P4 “You know people are on monthly injections of immune suppressants and stuff, maybe it could 
replace those…and diabetics as well, poor things have to inject loads of times per day” 
FG4P2 “My nephew is diabetic and has to give himself insulin all the time. He’s 15 you know and 
poor fella hates being different and kind of, standing out. Wouldn’t it be great if he could just 
stick on the patch instead? No one would even see it” 
FG5P1 “Wouldn’t they be great for babies in neonatal? The ‘preemies’ or even the sick babies and 
children that need to get lots of daily injections?” 
FG6P2 “Like insulin for diabetics. I think a patch like this would be great and they’d be checking 
their sugars anyway so they’d be sure it was working” 
 
Discussion 
The aim of this qualitative study was to determine the acceptability of microneedle technology for 
paediatric vaccination in a population of Cork city parents. According to the Health Service Executive 
(HSE) in Ireland, the target vaccine uptake rate for childhood immunisations is ≥95%. In their most 
recently available data, the Health Protection and Surveillance Centre (HPSC) reports that only the 6-
in-1 vaccine (D3, T3, P3, Hib3, Polio3 and HepB3) administered to children at 24 months of age in 2015 
had reached the target uptake rate of 95% (26). Therefore, there is scope for improving vaccine 
uptake, potentially through the introduction of novel immunisation methods, such as microneedle 
technology, as explored in this study. Whilst many sub-themes emerged, the five dominant themes 
that were revealed by thematic analysis were: (i) concern, (ii) suitability for paediatric use, (iii) 
potential for parental administration, (iv) the role of the healthcare professional and (v) special 
populations. Capturing the opinions of parents: the ultimate decision makers in paediatric vaccination, 
is crucial in the understanding of the eventual uptake of microneedle technology and therefore adds to 
literature currently available.  
Six focus groups compiled the opinions of 32 participants (29 female). Such a gender imbalance is not 
unusual: mothers are found to be more likely to participate in clinical research (21). Parental concern 
emerged as an overarching theme in this qualitative study. Participants alluded to established issues 
associated with conventional hypodermic needles, including phobias, pain, side effects and paediatric 
and parental anxiety (27-29). In addition, some parents expressed concern regarding school 
vaccination programmes and their potential to cause hysteria, particularly in association with the 
administration of adolescent vaccines (30, 31). These concerns may act as drivers for the acceptance 
of an alternative vaccine delivery system, such as microneedle technology. However, before a novel 
vaccine delivery system can be considered for acceptance, an effort must be made to address current 
vaccine concerns. Despite declaring that their children were fully vaccinated, one participant in this 
study (FG3P2) expressed opinions which questioned the safety and efficacy of vaccines. Benin et al 
would categorise this participant as “vaccine-hesitant”, accepting vaccination in spite of significant 
concerns (32, 33). Vaccine hesitancy presents a significant challenge, requiring a multidisciplinary 
approach (34).  Many studies have shown that increasing knowledge alone will not change behaviour 
and reduce vaccine hesitancy (35). Efforts focussed on determining how parents make decisions 
regarding vaccination, how their attitudes and beliefs develop, and where they obtain information, 
should contribute to better understanding of vaccine hesitancy (34, 36). This study revealed that even 
“vaccine-acceptors”, those who agree with or do not question vaccination (32), will question the 
safety and efficacy of novel immunisation methods (37). In agreement with published literature, our 
results suggest that lack of familiarity may act as a barrier to acceptance (19-21). However this barrier 
may be diminished by highlighting the advantages of microneedle-patch vaccines over conventional 
vaccination, by administering adult vaccines, such as influenza, using microneedle technology before 
progressing to paediatric use (6, 9, 38) and by securing healthcare professional endorsement (37). In 
addition, it is likely that parents would benefit from educational programmes that highlight the 
manner in which safety and efficacy assessments are conducted prior to licensure (37).  
Microneedle technology has been identified as ideal for paediatric use (19-21). However, this is the 
first study which asked participants to specifically consider a patch delivery system and this resulted 
in both the suitability and feasibility being challenged. Whilst participants recognised and 
acknowledged the benefits of the technology, concern was expressed regarding the wear-time 
required. Vaccinees must wait for the required periods of time for the microneedles to detach from the 
backing layer or dissolve into the skin before the patch can be removed. Participants expressed 
concern that paediatric tolerance of such a requirement would be low. In agreement with previous 
research, it was suggested that by creating a child-friendly version of the delivery system, children 
may be encouraged to leave the patch in place for the required amount of time (20). Various 
approaches have been developed to overcome the issue of prolonged wear-time (39). Two layered 
dissolving microneedles and arrowhead microneedles, consisting of a therapeutic polymer layer and a 
shaft, respectively, have been designed to deliver with greater efficiency (40, 41). Alternatively, a soft 
lithography approach based on a water soluble patch system has been introduced to increase delivery 
efficency by dissolving the patch after microneedle application (42). Given the parental concerns 
expressed, these approaches may warrant further investigation for the delivery of paediatric vaccines.  
A well-documented advantage of microneedle-patch vaccines is the potential for self-administration 
(1, 6-8, 19, 20). One US study which examined the usability and acceptability of microneedle patches 
for self-vaccination against influenza reported that when given self-administration options, intent to 
be immunised increased significantly, suggesting that microneedle technology could increase vaccine 
coverage (6). Of those participants who expressed a preference for microneedle-mediated 
immunisation, 72% preferred self-administration at home, 12% preferred self-administration in the 
presence of a healthcare professional and 16% preferred administration by a healthcare professional 
(6). While self-administration of paediatric vaccines is not feasible, participants were asked to 
consider the acceptability of parental administration. The  majority of participants in our study 
preferred vaccine administration by a healthcare professional, contradicting research by Birchall et al, 
who reported that 80% of participants disagreed with the statement “I don’t think I would want to 
administer microneedles to a child in my care” (19). In agreement with previous research, 
participants suggested that the inclusion of a delivery indicator would be a desirable augmentation of 
the current design (19, 20). A colour change was also suggested, combining dual benefits of 
increasing paediatric appeal and confirming delivery. Participants expressed concern that widespread 
parental administration could result in an intentional or unintentional reduction in immunisation rates 
and a decrease in population vaccine coverage overall. The national childhood immunisation 
programme, which recommends the administration of 15 vaccines from birth to approximately five 
years of age, is currently co-ordinated by general physicians (GP) and a series of Local Health Offices 
(23). The introduction of parental administration of vaccines would warrant the development of a 
National Immunisation Database, which would facilitate self-reporting of immunisation status and 
ensure vaccine traceability.    
The purpose of this study was to determine the acceptability of vaccine delivery by microneedle 
technology. However, similar to previous research, participants discussed alternative uses of this 
technology, particularly in the management of conditions where repeated injections are warranted, 
such as insulin in the management of diabetes, analgesics in the management of chronic pain, anti-
rheumatic agents in the management of arthritis and chemotherapeutic agents in the treatment of 
cancer (19). The clinical assessment of microneedle-mediated delivery of many drugs and 
macromolecules is already established (2, 43-47). Parental enthusiasm for microneedle-patch 
technology was increased by the exploration of alternative uses other than vaccination. It may be 
suggested that on-going monitoring in conditions such as diabetes is routine, thus providing 
continuous confirmation of efficacy, unlike vaccination, where confirmation of immunity is not 
routinely performed. By introducing microneedle technology for the management and treatment of 
these identified conditions, familiarity would be increased; there would be a tangible demonstration of 
safety and efficacy; and parental acceptance of microneedle-patch vaccines could be increased. In 
agreement with previous research, parents compared the delivery system to a sticking plaster and 
therefore expressed concern regarding the allergenic potential of microneedle-patch vaccines (19-21). 
It has been reported that the materials used in the fabrication of patch systems can cause skin irritation 
and allergic reactions (48).  Similar to transdermal patch products, the use of a hypoallergenic system 
to ensure  more widespread suitability and to reduce allergy potential would be necessary. 
Healthcare professionals including doctors, nurses and pharmacists will play a crucial role in the 
clinical success of microneedle-patch vaccines. Parent interactions with healthcare professionals are a 
key factor shaping parental attitudes to vaccination (49). An effective interaction can alleviate 
concerns of vaccine supportive parents and motivate a hesitant parent towards acceptance (50, 51). 
These parental concerns are likely to escalate with increased complexity of vaccination schedules, 
increased access to information sources of variable reliability (52) and the emergence of novel 
immunisation methods, such as microneedle technology. Healthcare professional endorsement of a 
novel technology is critical to its success. Previous research has reported a positive response to 
microneedle technology by healthcare professionals (6, 19). Continuous professional development 
(CPD) could facilitate training in this technology and in parent engagement, according to proposed 
recommendations (53-55). Guided by parental concerns expressed in relation to parental and self-
administration, it is likely healthcare professionals will retain the responsibility of vaccination, 
ensuring traceability and appropriate clinical management. . Limitations of this study include small 
sample size (n=32), participant self-selection and the necessary provision of factual information by 
the moderator. 
Conclusion 
This is the first study to explore parental acceptance of microneedle-patch vaccines. While 
participants in this study remained tentative regarding microneedle technology, it was revealed that 
this tentativeness could be reduced by healthcare professional endorsement. Therefore, this study has 
identified the role of healthcare professionals in disseminating information and providing support to 
parents. An increased awareness of developments in microneedle technology is needed to permit 
informed decision-making by parents.  
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